Zinlirvimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV-1 InfectionHIV Infections

66 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

1

Tybost

Gilead

Approved

12

Vemlidy

Gilead

Approved

—3

Taxol

Teva

Approved

—4

Cabenuva

GSK

Approved

—5

Niacor

AbbVie

Approved

—6

Epidiolex

Jazz Pharmaceuticals

Approved

—7

Renvela

Sanofi

Approved

—8

Ziagen

GSK

Approved

—9

Bayer Aspirin

Bayer

Approved

—10

Crestor

AstraZeneca

Approved

—Show 43 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

HIV-1 infection3 trials

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruiting·Gilead·Phase 2·NCT05729568·83 enrolled

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Completed·Gilead·Phase 1·NCT04811040·32 enrolled

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Recruiting·Gilead·Phase 3·NCT07683000·590 enrolled

HIV Infections1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Recruiting·Gilead·Phase 3·NCT07682961·590 enrolled

Details

Drug Info

Related News